Biotech Values

[steveporsche]

Thanks David. Talk about a complete answer to a question! I do not like the difference in HRs for pain vs. no-pain shown in Slide 18.

What troubles me most about Impact: My calcs. show that approximately 40% of patients will on trial for 26 months or less, and approximately 20% at 22 months or less. In 9901/9902a the curves separate nicely post 24 months. Do you think DNDN management really blew it with the SPA change throwing out those 56 events? What are your thoughts on this?

Thanks